NCT03538028 - A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

October 7, 2020

Study Completion Date

October 7, 2020

Conditions

Cervical CancerMicrosatellite Instability (MSI)-High Endometrial CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])Esophageal CancerHepatocellular CarcinomaMelanoma (Uveal Melanoma Excluded)Merkel Cell CarcinomaMesotheliomaMSI-high Colorectal CancerNon-small Cell Lung Cancer (NSCLC)Ovarian CancerSquamous Cell Carcinoma of the Head and Neck (SCCHN)Small Cell Lung Cancer (SCLC)Renal Cell Carcinoma (RCC)Triple-negative Breast CancerUrothelial CarcinomaDiffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL

INCAGN02385

INCAGN02385 administered as an intravenous infusion over 30 minutes.

Trial Locations (4)

28078

Carolina BioOncology Institute, Huntersville

37232

Vanderbilt University Medical Center, Nashville

90025

The Angeles Clinic and Research Center, Los Angeles

07601

Hackensack Medical Center, Hackensack